{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:22:20Z","timestamp":1791246140136,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":1559,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1038\/mt.2012.84","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T12:40:13Z","timestamp":1336480813000},"page":"1410-1416","source":"Crossref","is-referenced-by-count":103,"title":["Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B"],"prefix":"10.1016","volume":"20","author":[{"given":"Federico","family":"Mingozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyrie C","family":"Edmonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangzhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Fraser","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia E","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A","family":"High","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2012.84_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat Rev Genet"},{"key":"10.1038\/mt.2012.84_bib2","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","article-title":"A coagulation factor IX-deficient mouse model for human hemophilia B","volume":"90","author":"Lin","year":"1997","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib3","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1073\/pnas.86.24.10095","article-title":"Canine hemophilia B resulting from a point mutation with unusual consequences","volume":"86","author":"Evans","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2012.84_bib4","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/blood.V88.9.3451.bloodjournal8893451","article-title":"A deletion mutation causes hemophilia B in Lhasa Apso dogs","volume":"88","author":"Mauser","year":"1996","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib5","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.94.21.11563","article-title":"A factor IX-deficient mouse model for hemophilia B gene therapy","volume":"94","author":"Wang","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2012.84_bib6","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.84_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/13518","article-title":"Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors","volume":"5","author":"Snyder","year":"1999","journal-title":"Nat Med"},{"key":"10.1038\/mt.2012.84_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1038\/mt.2012.84_bib11","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2012.84_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br J Haematol"},{"issue":"suppl. 2","key":"10.1038\/mt.2012.84_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2009.02197.x","article-title":"Assessing risk factors: prevention of inhibitors in haemophilia","volume":"16","author":"Chambost","year":"2010","journal-title":"Haemophilia"},{"key":"10.1038\/mt.2012.84_bib14","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/mt.2009.159","article-title":"Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B","volume":"17","author":"Cao","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.84_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/mthe.2001.0441","article-title":"Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9","volume":"4","author":"Fields","year":"2001","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.84_bib16","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/104303402760128513","article-title":"Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy","volume":"13","author":"Herzog","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2012.84_bib17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","article-title":"Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer","volume":"110","author":"Cao","year":"2007","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood-2004-03-0847","article-title":"Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer","volume":"104","author":"Dobrzynski","year":"2004","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/hep.24230","article-title":"Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk","volume":"53","author":"M\u00e1trai","year":"2011","journal-title":"Hepatology"},{"key":"10.1038\/mt.2012.84_bib20","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2012.84_bib21","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib22","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib23","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","article-title":"Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A","volume":"344","author":"Roth","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2012.84_bib24","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib25","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2516.2006.01342.x","article-title":"Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy","volume":"13","author":"Field","year":"2007","journal-title":"Haemophilia"},{"key":"10.1038\/mt.2012.84_bib27","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/blood-2003-11-4075","article-title":"Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia","volume":"103","author":"Stasi","year":"2004","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/HAB-2004-13301","article-title":"In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody","volume":"13","author":"Sidner","year":"2004","journal-title":"Hum Antibodies"},{"key":"10.1038\/mt.2012.84_bib29","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2011-03-344051","article-title":"Immunologic effects of rituximab on the human spleen in immune thrombocytopenia","volume":"118","author":"Audia","year":"2011","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib30","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","article-title":"The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab","volume":"29","author":"Arad","year":"2011","journal-title":"Vaccine"},{"key":"10.1038\/mt.2012.84_bib31","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib32","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood.V93.6.1875.406k16_1875_1881","article-title":"The rhesus macaque as an animal model for hemophilia B gene therapy","volume":"93","author":"Lozier","year":"1999","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib33","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1084\/jem.20100209","article-title":"IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells","volume":"207","author":"Grinberg-Bleyer","year":"2010","journal-title":"J Exp Med"},{"key":"10.1038\/mt.2012.84_bib34","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2012.84_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/156652311796150354","article-title":"Immune responses to AAV in clinical trials","volume":"11","author":"Mingozzi","year":"2011","journal-title":"Curr Gene Ther"},{"key":"10.1038\/mt.2012.84_bib36","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood.V116.21.3765.3765","article-title":"Rabbit anti-thymocyte globulin (rATG) administrated concomitantly with liver delivery of AAV2-hFIX can promote inhibitor formation in rhesus macaques","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatology"},{"key":"10.1038\/mt.2012.84_bib38","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1073\/pnas.1012753108","article-title":"Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy","volume":"108","author":"Jayandharan","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2012.84_bib39","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fmicb.2011.00194","article-title":"Innate Immune Responses to AAV Vectors","volume":"2","author":"Rogers","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1038\/mt.2012.84_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2010-06-289009","article-title":"Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9","volume":"117","author":"Allacher","year":"2011","journal-title":"Blood"},{"key":"10.1038\/mt.2012.84_bib42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2516.2007.01446.x","article-title":"Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX","volume":"16","author":"Barnes","year":"2010","journal-title":"Haemophilia"},{"key":"10.1038\/mt.2012.84_bib43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2516.2006.01215.x","article-title":"Rituximab for adolescents with haemophilia and high titre inhibitors","volume":"12","author":"Fox","year":"2006","journal-title":"Haemophilia"},{"key":"10.1038\/mt.2012.84_bib44","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2516.2010.02458.x","article-title":"Surgery-associated acquired haemophilia and response to combined rituximab and cyclosporine treatment","volume":"17","author":"Kam","year":"2011","journal-title":"Haemophilia"},{"key":"10.1038\/mt.2012.84_bib45","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/pbc.23231","article-title":"Rituximab and cyclosporine therapy for accelerated phase Chediak-Higashi syndrome","volume":"57","author":"Ogimi","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1038\/mt.2012.84_bib46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2141.2009.07594.x","article-title":"Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants","volume":"145","author":"Svahn","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1038\/mt.2012.84_bib47","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.84_bib48","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1016\/S1525-0016(16)39183-3","article-title":"Pre-existing immunity to different adeno-associated virus serotypes in serum and synovial fluid of RA patients: implications for vector efficacy","volume":"17","author":"Vervoordeldonk","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.84_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2009.157","article-title":"High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency","volume":"17","author":"Ayuso","year":"2010","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2012.84_bib50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616325710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616325710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T08:43:48Z","timestamp":1594111428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616325710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1525001616325710"],"URL":"https:\/\/doi.org\/10.1038\/mt.2012.84","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}